Benzinga examined the prospects for many investors' favorite stocks over the last week — here's a look at some of our top ...

San Francisco telehealth company Hims & Hers saw its stock plunge more than 30% earlier this week after a partnership with ...

Novo Nordisk A/S (NYSE:NVO) is one of the 12 stocks that will make you rich in 10 years. On June 23, the company discontinued ...

Investing.com -- Markets closed the week positively, with stocks reaching a record high on Friday. The optimism was largely ...

Meta Platforms, Inc. (NASDAQ:META) is one of the 13 Best Long Term Growth Stocks to Invest in Right Now. On June 24, DBS analyst Sachin Mittal maintained a Buy rating on Meta Platforms, Inc.

Hims & Hers Health, Inc. (NYSE:HIMS) is one of the 10 Stocks Delivering Eye-Popping Gains. Hims & Hers rebounded by 11.76 ...

Novo Nordisk is expanding access to its drug Wegovy through a new partnership with WeightWatchers, days after cutting ties with telehealth firm Hims & Hers. Starting July 1, WeightWatchers will ...

Under the deal, cash-paying patients can access a month’s supply of Wegovy through the Danish drugmaker’s Novocare pharmacy for $299. The one-time price will also be available through Novo’s other ...

Gun-related suicides in the U.S. reached record highs for the third straight year in 2023, a new report on gun violence says.

On April 29, 2025, Hims announced a long-term collaboration with Novo Nordisk, starting with the immediate sale of "a bundled offering of Novo Nordisk's FDA-approved Wegovy on the Hims & Hers platform ...

Direct access to Wegovy® (semaglutide) will no longer be available through Hims & Hers Health, as Novo Nordisk has ended its short-lived partnership ...